Align Technology Reports $1.04 Billion Revenue and $112.8 Million Net Income in Q1 2026

Align Technology, Inc. reported a net revenue of $1.04 billion for the first quarter of 2026, marking a 6.2% increase from $979.3 million in the same period of 2025. The company's net income rose to $112.8 million, or $1.57 per diluted share, compared to $93.2 million, or $1.27 per diluted share, in the prior year. This growth in profitability was supported by a gross profit of $736.6 million, up from $680.1 million, reflecting a gross margin improvement from 69.5% to 70.8%. The increase in revenue was primarily driven by a 7.4% rise in Clear Aligner revenues, which reached $856 million, alongside a modest 0.9% increase in revenues from the Systems and Services segment.

The company experienced notable changes in its operational metrics, with Clear Aligner case volume increasing by 6.7% year-over-year. The number of trained doctors receiving shipments rose to 88,100, a 3.3% increase from the previous year. Additionally, the average revenue per Clear Aligner case shipment increased slightly from $1,240 to $1,250. Align's international operations also contributed positively, with revenues from Switzerland and other international markets showing growth, although U.S. revenues declined slightly.

Align Technology has made strategic moves, including an immaterial acquisition that added $18.6 million to goodwill in the Systems and Services segment. The company also reported a significant increase in legal settlements, which totaled $30.6 million for the quarter, compared to $4.2 million in the prior year. This increase reflects ongoing legal challenges, including antitrust class actions and patent litigation. The company has also been proactive in managing its workforce, with a reported employee count of 20,275, a decrease of 4.4% from the previous year, as part of its restructuring efforts to align with current market conditions.

Looking ahead, Align Technology remains focused on its strategic growth drivers, including international expansion and enhancing patient demand for its products. The company anticipates continued challenges from macroeconomic factors, including inflation and geopolitical tensions, which may impact consumer confidence and discretionary spending. However, Align is optimistic about its ability to navigate these challenges through innovation and operational efficiencies. The company expects to maintain sufficient liquidity, with cash and cash equivalents totaling $1.06 billion as of March 31, 2026, and access to a $300 million revolving credit facility.